Ginsenoside Rh1 人参皂苷 Rh1; Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1,98.0%
产品编号:Bellancom-N0604| CAS NO:63223-86-9| 分子式:C36H62O9| 分子量:638.87
Ginsenoside Rh1 是从 Panax Ginseng 根部分离的。 Ginsenoside Rh1 抑制 PPAR-γ,TNF-α,IL-6 和 IL-1β 的表达。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Ginsenoside Rh1 人参皂苷 Rh1; Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1
产品介绍 | Ginsenoside Rh1 (Prosapogenin A2) 抑制 PPAR-γ,TNF-α,IL-6 和 IL-1β 的表达。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β. | ||||||||||||||||
体外研究 |
The effect of Ginsenoside Rh1 is examined on adipogenesis in 3T3-L1 cells. Ginsenoside Rh1 potently inhibits the adipogenesis, as assessed by Oil-red O staining and lipid contents in 3T3-L1 adipocytes. Ginsenoside Rh1, at concentrations of 50 μM and 100 μM, inhibit the adipogenesis by 50% and 63%, respectively.The expression levels of adipocytespecific genes such as PPAR-γ, C/EBP-α, FAS, aFABP and some genes are examined during early phase of differentiation such as Pref-1, C/EBP-δ and Glucocorticoid receptor (GR). After the treatment with Ginsenoside Rh1 in 3T3-L1 cells, mRNA is extracted on 18 h and 24 h for Pref-1, C/EBP-δ and GR and day 8 for PPAR-γ, C/EBP-α, FAS, aFABP. Then, the expression profiles of adipocyte-specific genes are investigated by RT-PCR. PPAR-γ, C/EBP-α, FAS, and aFABP expressions are significantly increased in DMI-stimulated differentiated adipocyte compared to those of non-stimulated adipocyte cells. However, treatment with DMI in the presence of Ginsenoside Rh1 significantly suppresses the expression levels of PPAR-γ, C/EBP-α, FAS, and aFABP in a dose- dependent manner, whereas the expression levels of Pref-1, C/EBP-δ and GR are not affected. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
When high-fat diet (HFD) fed mice for 8 weeks, body and epididymal fat weight gains are significantly increased compared to those of low-fat diet (LFD)-fed mice. However, when Ginsenoside Rh1 is treated in HFD-fed mice, body and epididymal fat weight gains are significantly decrease compared with those of the HFD-fed mice. TG, glucose, insulin, total cholesterol, and HDL levels in the blood are significantly increased in HFD-fed mice group compared to LFD-fed mice group. Treatment with Ginsenoside Rh1 in HFD-fed mice significantly lowers TG level alone. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
When high-fat diet (HFD) fed mice for 8 weeks, body and epididymal fat weight gains are significantly increased compared to those of low-fat diet (LFD)-fed mice. However, when Ginsenoside Rh1 is treated in HFD-fed mice, body and epididymal fat weight gains are significantly decrease compared with those of the HFD-fed mice. TG, glucose, insulin, total cholesterol, and HDL levels in the blood are significantly increased in HFD-fed mice group compared to LFD-fed mice group. Treatment with Ginsenoside Rh1 in HFD-fed mice significantly lowers TG level alone. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (156.53 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |
符号 |
![]() GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302 |
危险品运输编码 | NONH for all modes of transport |
RTECS号 | LZ6428000 |
产品名: | (S)Ginsenoside-Rh1 |
CAS号: | 63223-86-9 |
制造商/供应商: | 西域试剂 网站:www.hzbp.cn 邮件:13911702513@139.com |
2. 合成/成分数据
产品名: | (S)Ginsenoside-Rh1 |
别名: | Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1; Ginsenoside-Rh1 |
分子式: | C36H62O9 |
分子量: | 638.87 |
3. 急救措施
吸入后: | 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。 |
皮肤接触后: | 用大量的水冲洗,移除污染的衣服和鞋子。 |
眼睛接触后: | 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。 |
吞食后: | 如果吞食,用大量纯净水漱口;呼叫医生。 |
4. 消防措施
适当的灭火剂: | 雾状水,二氧化碳,干粉或泡沫。 |
防护设备: | 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。 |
5. 泄漏应急处理
安全防范措施: | 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。 |
清洁/收集措施: | 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末; 使用酒精擦洗表面和设备除去污渍; 根据第11条处理被污染的材料。 |
6. 处理和储存
安全处理说明: | 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。 |
储存: |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
7. 接触控制和个人防护
呼吸设备: | NIOSH / MSHA认可的呼吸器。 |
双手保护: | 耐化学腐蚀的橡胶手套。 |
眼睛防护: | 化学安全护目镜。 |
8. 稳定性和反应活性
稳定性: | 按照说明存储是稳定的;避免强氧化剂。 |
热分解/其他要避免的情况: | 避免光和热。 |
9. 毒性资料
急性毒性: | 无可用资料。 |
主要刺激性影响: | 无可用资料。 |
在皮肤上: | 无可用资料。 |
对眼睛: | 无可用资料;可能具有刺激性。 |
10. 生态资料
一般注意事项: | 无可用资料。 |
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。 |
12. 运输信息
正确的运输名称: | 无 |
非危险品运输: | 这种物质被视为非危险品运输。 |
13. 法规信息
尚未有针对此产品作出的化学安全性评估。 |
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。 |
- 12. Yongshen Ren, Jiao Ai, Xinqiao Liu, Shuai Liang, Yao Zheng, Xin Deng, Yan Li, Jing Wang, Xukun Deng, Lin-Lin Chen, Anticoagulant active ingredients identification of total saponin extraction of different Panax medicinal plants based on grey relational anal
- 11. Hong Zhang, Jia-Ming Jiang, Dan Zheng, Ming Yuan, Zhi-Ying Wang, Hong-Mei Zhang, Chang-Wu Zheng, Lian-Bo Xiao, Hong-Xi Xu, A multidimensional analytical approach based on time-decoupled online comprehensive two-dimensional liquid chromatography coupled wit
- 10. Hong Zhang, Jia-Ming Jiang, Dan Zheng, Ming Yuan, Zhi-Ying Wang, Hong-Mei Zhang, Chang-Wu Zheng, Lian-Bo Xiao, Hong-Xi Xu, A multidimensional analytical approach based on time-decoupled online comprehensive two-dimensional liquid chromatography coupled wit
- 9. Hong Zhang, Jia-Ming Jiang, Dan Zheng, Ming Yuan, Zhi-Ying Wang, Hong-Mei Zhang, Chang-Wu Zheng, Lian-Bo Xiao, Hong-Xi Xu, A multidimensional analytical approach based on time-decoupled online comprehensive two-dimensional liquid chromatography coupled wit
- 8. Qin, Z., Jia, M., Yang, J. et al. Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug–drug interactions. Chin Med 15, 69 (2020). https://doi.o
- 7. Zhang, Hong-Mei, et al. "Holistic quality evaluation of commercial white and red ginseng using a UPLC-QTOF-MS/MS-based metabolomics approach." Journal of pharmaceutical and biomedical analysis 62 (2012): 258-273.https://doi.org/10.1016/j.jpba.2012.01.010
- 6. 越皓,周东月,张美玉,张琰,戴雨霖,郑飞,朱英豪.红参中原人参三醇型皂苷组在肠道菌群中体外转化及对肠道菌群的作用[J].应用化学,2021,38(03):323-330.
- 5. 夏晚霞, 张尚微, 葛亚中,等. 乳酸菌发酵转化人参皂苷[J]. 现代食品科技, 2018, 34(09):136-142.
- 4. 张琰, 李方彤, 韩铭鑫,等. 通过RRLC-Q-TOF MS和UPLC-QQQ MS分析原人参三醇型皂苷在人肠道菌群中的代谢产物[J]. 质谱学报, 2020(1):66-75.
- 3. 张博, 孙秀丽, 郭云龙,等. 液质联用技术分析不同产地不同年限人参的化学成分[J]. 中国实验方剂学杂志, 2020年26卷8期, 206-212页, ISTIC PKU CSCD CA, 2020.
- 2. 董坤园, 于澎, 熊金路,等. 基于高效液相色谱图谱结合化学计量学的红参指纹图谱研究[J]. 食品安全质量检测学报, 2019, 010(021):7316-7321.
- 1. 钟雅婷 茅仁刚 宋纯清 等. RP-HPLC同时测定西洋参总皂苷转化产物中人参皂苷Rg1 Rh1 Rd Rg3和C-K的含量[J]. 江西中医药 2012 43(8):61-64.

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存